MCID: PTT009
MIFTS: 53

Pituitary Gland Disease

Categories: Endocrine diseases, Rare diseases

Aliases & Classifications for Pituitary Gland Disease

MalaCards integrated aliases for Pituitary Gland Disease:

Name: Pituitary Gland Disease 12 15 17
Pituitary Dysfunction 54 70
Pituitary Diseases 54 70
Pituitary Deficiency 58
Pituitary Disorders 42
Pituitary Disease 12

Classifications:

Orphanet: 58  
Rare endocrine diseases


External Ids:

Disease Ontology 12 DOID:53
ICD9CM 34 253.1
ICD10 32 E23.6 E23.7
ICD10 via Orphanet 33 E23.0
UMLS via Orphanet 71 C0020635
Orphanet 58 ORPHA101957
UMLS 70 C0029493 C0032002 C0281947

Summaries for Pituitary Gland Disease

MedlinePlus : 42 Your pituitary gland is a pea-sized gland at the base of your brain. The pituitary is the "master control gland" - it makes hormones that affect growth and the functions of other glands in the body. With pituitary disorders, you often have too much or too little of one of your hormones. Injuries can cause pituitary disorders, but the most common cause is a pituitary tumor.

MalaCards based summary : Pituitary Gland Disease, also known as pituitary dysfunction, is related to hypothyroidism, central, with testicular enlargement and hypopituitarism, and has symptoms including seizures, tremor and back pain. An important gene associated with Pituitary Gland Disease is PRL (Prolactin), and among its related pathways/superpathways are Peptide ligand-binding receptors and Aldosterone synthesis and secretion. The drugs Cefuroxime and Cefazolin have been mentioned in the context of this disorder. Affiliated tissues include pituitary gland, pituitary and brain, and related phenotypes are endocrine/exocrine gland and growth/size/body region

Disease Ontology : 12 An endocrine system disease that is located in the pituitary gland.

Wikipedia : 73 A pituitary disease is a disorder primarily affecting the pituitary... more...

Related Diseases for Pituitary Gland Disease

Diseases related to Pituitary Gland Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 439)
# Related Disease Score Top Affiliating Genes
1 hypothyroidism, central, with testicular enlargement 32.1 TRH PROP1 PRL POU1F1
2 hypopituitarism 31.4 TRH RNU4ATAC PROP1 PRL POU1F1 POMC
3 growth hormone deficiency 31.0 HESX1 GHRH GH1
4 pituitary tumors 30.9 SST PROP1 PRL POMC MEN1 IGF1
5 acromegaly 30.6 TRH SST PRL POMC MEN1 INS
6 diabetes insipidus 30.5 PRL POMC INS GH1 CRH AVP
7 multiple endocrine neoplasia 30.5 SST POMC MEN1 AIP
8 lymphocytic hypophysitis 30.5 POMC GH1
9 insulin-like growth factor i 30.5 SST PRL INS IGF1 GHRH GH1
10 hypothyroidism, congenital, nongoitrous, 4 30.5 PROP1 PRL POU1F1 POMC GH1
11 adenoma 30.5 TRH SST PRL POU1F1 POMC MEN1
12 secondary adrenal insufficiency 30.5 INS IGF1 AVP
13 hypogonadism 30.5 PROP1 PRL INS IGF1 GNRH1
14 sexual disorder 30.5 PRL POMC INS IGF1 GNRH1
15 adrenal adenoma 30.4 POMC MEN1 INS CRH
16 hypoglycemia 30.4 SST PRL POMC INS IGF1 GH1
17 polycystic ovary syndrome 30.4 PRL INS IGF1 GNRH1 GH1
18 dwarfism 30.4 RNU4ATAC GHRH GH1
19 multiple endocrine neoplasia, type i 30.4 SST PRL POMC MEN1 INS GHRH
20 holoprosencephaly 30.3 PROP1 POU1F1 LHX3 HESX1
21 congenital hypopituitarism 30.3 PROP1 HESX1 GHRH
22 non-functioning pituitary adenoma 30.3 SST GH1
23 hyperthyroidism 30.3 TRH SST PRL POMC INS IGF1
24 pituitary hypoplasia 30.3 PRL POU1F1 LHX3 HESX1 GH1
25 fibrous dysplasia/mccune-albright syndrome 30.3 PRL GH1
26 hyperprolactinemia 30.3 TRH SST PRL POMC INS IGF1
27 central precocious puberty 30.3 IGF1 GNRH1 GH1
28 pituitary adenoma, prolactin-secreting 30.3 TRH SST PRL POU1F1 POMC MIR93
29 hormone producing pituitary cancer 30.3 SST PRL POMC MEN1 IGF1 GHRH
30 amenorrhea 30.3 TRH PRL POMC INS IGF1 GNRH1
31 galactorrhea 30.3 PRL IGF1
32 liver cirrhosis 30.3 SST INS IGF1 GHRH AVP
33 anorexia nervosa 30.3 PRL POMC INS IGF1 GHRH GH1
34 gynecomastia 30.3 PRL POMC GNRH1
35 pituitary hormone deficiency, combined, 1 30.3 POU1F1 LHX3 HESX1
36 adenohypophysitis 30.3 TRH PRL POMC GH1
37 substance abuse 30.3 PRL POMC INS CRH
38 cranial nerve palsy 30.3 PRL POMC AVP
39 graves disease 1 30.3 TRH POMC INS
40 hypothalamic obesity 30.2 INS IGF1 GHRH
41 fibromyalgia 30.2 POMC IGF1 CRH
42 hyperandrogenism 30.2 PRL POMC INS IGF1 GNRH1
43 familial isolated pituitary adenoma 30.2 MEN1 AIP
44 craniopharyngioma 30.2 TRH PROP1 PRL POU1F1 INS IGF1
45 inappropriate adh syndrome 30.2 POMC CRH AVP
46 sleep disorder 30.2 PRL POMC INS IGF1 CRH
47 impotence 30.2 PRL POMC INS GNRH1
48 gigantism 30.2 PRL GHRH GH1 AIP
49 mccune-albright syndrome 30.1 SST PRL MEN1 IGF1 GH1
50 fibrous dysplasia 30.1 SST PRL IGF1 GHRH GH1

Graphical network of the top 20 diseases related to Pituitary Gland Disease:



Diseases related to Pituitary Gland Disease

Symptoms & Phenotypes for Pituitary Gland Disease

UMLS symptoms related to Pituitary Gland Disease:


seizures; tremor; back pain; headache; syncope; pain; chronic pain; sciatica; vertigo/dizziness; sleeplessness

MGI Mouse Phenotypes related to Pituitary Gland Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.21 AIP CRH GHRH GNRH1 HESX1 IGF1
2 growth/size/body region MP:0005378 10.17 AIP CRH GHRH GNRH1 HESX1 IGF1
3 homeostasis/metabolism MP:0005376 10.13 AIP AVP CRH GHRH GNRH1 IGF1
4 immune system MP:0005387 9.9 AVP CRH GHRH GNRH1 IGF1 INS
5 liver/biliary system MP:0005370 9.56 AIP CRH GHRH GNRH1 INS MEN1
6 nervous system MP:0003631 9.5 AVP CRH GHRH GNRH1 HESX1 IGF1

Drugs & Therapeutics for Pituitary Gland Disease

Drugs for Pituitary Gland Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 192)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
2
Cefazolin Approved Phase 4 25953-19-9 33255 656510
3
Cefdinir Approved Phase 4 91832-40-5 6915944
4
Sulfamethoxazole Approved Phase 4 723-46-6 5329
5
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
6
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
7
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
8
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
9
Racepinephrine Approved Phase 4 329-65-7 838
10
Morphine Approved, Investigational Phase 4 57-27-2 5288826
11
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
12
Ibuprofen Approved Phase 4 15687-27-1 3672
13
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
14
Octreotide Approved, Investigational Phase 4 83150-76-9 6400441 383414
15
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
16
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
17
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
18
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
19
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
20
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
21
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605
22
Lactitol Approved, Investigational Phase 4 585-86-4 157355
23
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
24
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
25
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
26
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
27 cefuroxime axetil Phase 4
28 Cephalosporins Phase 4
29 Folic Acid Antagonists Phase 4
30 Cytochrome P-450 Enzyme Inhibitors Phase 4
31 Clindamycin phosphate Phase 4
32 Clindamycin palmitate Phase 4
33 Antiparasitic Agents Phase 4
34 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
35 Antiprotozoal Agents Phase 4
36 Anti-Infective Agents Phase 4
37 Antimalarials Phase 4
38 Hormone Antagonists Phase 4
39 Epinephryl borate Phase 4
40 Anti-Inflammatory Agents Phase 4
41 Gastrointestinal Agents Phase 4
42 Antiemetics Phase 4
43 Antineoplastic Agents, Hormonal Phase 4
44 glucocorticoids Phase 4
45 Neuroprotective Agents Phase 4
46 Methylprednisolone Acetate Phase 4
47 Protective Agents Phase 4
48 Immunosuppressive Agents Phase 4
49 Immunologic Factors Phase 4
50 triamcinolone acetonide Phase 4

Interventional clinical trials:

(show top 50) (show all 154)
# Name Status NCT ID Phase Drugs
1 A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Evaluating the Impact of Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Unknown status NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
2 Effect of Dexmedetomidine as Anesthetic Coadjuvant on Plasmatic Cortisol Response in Transsphenoidal Surgery for Pituitary Tumors Unknown status NCT02549768 Phase 4 Dexmedetomidine;Sodium Chloride 0.9%
3 Comparative Low and High Dose of Dexmedethomidine Can Stabilize Hemodynamics and Blood Loss in Pituitary Tumor Removal by Transphenoid Approach Unknown status NCT03132259 Phase 4 high dose dexmedethomidine;low dose dexmedethomidine
4 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
5 Randomized, Double-Blind, Placebo-Controlled Trial Comparing Opioid-Sparing and Opioid-Containing Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors Completed NCT02351700 Phase 4 IV Caldolor (IV Ibuprofen);IV Ibuprofen placebo
6 A Phase IV Open-label Study of Predictive Markers in Growth Hormone Deficient Pre-pubertal Children Treated With Saizen® Completed NCT01187550 Phase 4 Recombinant human growth hormone (r-hGH)
7 Evaluation of Efficacy and Hypothalamus-pituitary-adrenal Axis Suppression Due to a Single Intrabursal Injection of Corticosteroids in Patients With Shoulder Calcific Tendinopathy Completed NCT01652495 Phase 4 methylprednisolone acetate;Triamcinolone Acetonide
8 Anterior Pituitary Hormone Replacement in Traumatic Brain Injury Completed NCT00957671 Phase 4 Recombinant human growth hormone
9 Does Surgical Debulking Of Pituitary Adenomas Improve Responsiveness To Octreotide LAR In The Treatment Of Acromegaly: An Investigator-Initiated Study Completed NCT01371643 Phase 4 Octreotide LAR
10 An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment Active, not recruiting NCT01794793 Phase 4 Pasireotide;Cabergoline;Pasireotide
11 The Effects of Infraorbital Nerve Block With Dexmedetomidine Added to Bupivacaine on Fentanyl Requirement During Endoscopic Transsphenoidal Approach to Remove Pituitary Tumor: Prospective Randomized Double Blinded Control Study Not yet recruiting NCT04785222 Phase 4 dexmedetomidine 5 mcg mixed with 0.5% plain bupivacaine
12 The Effect of Aging on the Isolated Pituitary Response to Gonadotropin Releasing Hormone at Baseline and With Low Dose Estrogen Administration Unknown status NCT00386022 Phase 2, Phase 3 GnRH;NAL-GLU GnRH antagonist;Estrogen patch
13 Impact of Omitting GnR-antagonist on Ovulation Trigger Day in the Fresh Autologous IVF/ICSI Cycles Unknown status NCT03044756 Phase 2, Phase 3 Omit Citrotide 0.25 dose on the day of triggering of ovulation
14 Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Unknown status NCT02419664 Phase 3
15 A Phase III, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess Efficacy and Safety of LB03002 Administered Weekly in Adults With Growth Hormone Deficiency. Completed NCT00294619 Phase 3 growth hormone
16 A Phase III, Open-label, Uncontrolled, Multicentre, Rollover Study to Assess Safety and Efficacy of LB03002 Administered Weekly in Adults With Growth Hormone Deficiency Completed NCT00596037 Phase 3 Growth hormone - LB03002
17 Open-Label, Parallel-Group, Randomized, Multicenter Phase III Trial to Compare the Efficacy and Safety of a 250 mcg SC Dose of MSJ-0011 to a 5,000 IU IM Dose of Urinary Human Chorionic Gonadotropin in Inducing Ovulation in Japanese Women Diagnosed With Anovulation or Oligo-Ovulation Secondary to Hypothalamic-Pituitary Dysfunction or Polycystic Ovarian Syndrome, and Who Are Undergoing Ovulation Induction With Follitropin Alfa Completed NCT01653743 Phase 3 MSJ-0011;urinary hCG (u-hCG);Follitropin alpha
18 A Prospective, Single-Center, Open-Label, Randomized Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Regimens of Oral Contraceptive Pills Completed NCT00117273 Phase 3 Seasonale [levonorgestrel (LNG)/ethinyl estradiol (EE)];Seasonique (LNG/EE and EE);Portia (LNG/EE)
19 A Multicenter, Phase 3, Randomized, Open-label, Active-controlled, Parallel-group Trial Investigating the Safety, Tolerability, and Efficacy of TransCon hGH Administered Once a Week Versus Standard Daily hGH Replacement Therapy Over 52 Weeks in Prepubertal Children With Growth Hormone Deficiency (GHD) Completed NCT02781727 Phase 3 Once weekly subcutaneous injection of TransCon hGH;Once daily subcutaneous injection of Genotropin
20 Clinical Assessment of the Treatment With Diazoxide in Children Suffering From Obesity and Hyperinsulinemia Secondary to Surgery of Hypothalamic-pituitary Lesions Completed NCT00306683 Phase 3 DIAZOXIDE
21 Phase IIIB, International, Single Group, Open Study to Define an Optimal Monitoring of IGF-1 in Children Treated With NutropinAq, Using a Novel Capillary Blood Collection Method Completed NCT00234533 Phase 3 Somatropin (rDNA origin)
22 Parallel-Group Comparative Study of SJ-0021 and Purified Pituitary Gonadotropin in Subjects With Amenorrhea I or Anovulatory Cycles - Phase III Single-Blind Study Completed NCT01185782 Phase 3 Gonalef® (Follitropin alfa);Purified pituitary gonadotropin (Fertinorm-P®)
23 Somatostatin and Dopamine Receptors Expression in Non-functioning Pituitary Adenomas and Resistant Prolactinomas: Correlation With in Vitro and in Vivo Responsiveness to Somatostatin Analogs and Dopamine Agonist Completed NCT01620138 Phase 2, Phase 3 Pasireotide;cabergoline
24 Dopamine Agonist Cabergoline in Residual Clinically Nonfunctioning Pituitary Adenoma After Transphenoidal Surgery: A Single Center, Open Label and Randomized Clinical Trial Completed NCT03271918 Phase 3 Cabergoline
25 fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD Completed NCT03305016 Phase 3 TransCon hGH
26 An Open-Label Phase 3 Study of the Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess Recruiting NCT03882034 Phase 3 Pegvisomant
27 Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas (NFPAs) - a Randomized Controlled Trial Recruiting NCT02288962 Phase 3 cabergoline
28 The Efficacy, Safety and Tolerability of TransCon hGH Administered Weekly Versus Daily hGH in Prepubertal Children With Growth Hormone Deficiency: a Randomized, Open-lable, Active-controlled, Parallel-group Study in China Recruiting NCT04326374 Phase 3 TransCon hGH;daily hGH
29 enliGHten: A Multicenter, Phase 3, Long-Term, Open-Label Trial Investigating Safety and Efficacy of TransCon hGH Administered Once-Weekly in Children With Growth Hormone Deficiency (GHD) Who Have Completed a Prior TransCon hGH Clinical Trial Active, not recruiting NCT03344458 Phase 3 TransCon hGH
30 Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma From an Endocrinological Point of View (MERGE Study): a Randomized, Phase 3 Trial Not yet recruiting NCT03439709 Phase 3 Lanreotide 60Mg Solution for Injection
31 Radiotherapy Plus Concomitant Temozolomide for Refractory Pituitary Adenomas,A Randomized,Double-blind, Placebo-controlled Phase II Trial Not yet recruiting NCT04244708 Phase 2, Phase 3 Radiotherapy plus temozolomide
32 Pilot Study of Pasireotide LAR Treatment of Silent Corticotrophin Pituitary Tumors and Effects on Plasma Levels of POMC Unknown status NCT02749227 Phase 2 Pasireotide LAR
33 A Multicentre, Prospective, Open Study to Describe the Effects of rhLH Supplement in Women With Hyporesponse to rFSH After Pituitary Downregulation. Unknown status NCT01029470 Phase 2 Luveris
34 Study of Thyrotropin Releasing Hormone in Patients With Thyroid or Pituitary Abnormalities Completed NCT00054756 Phase 2 TRH (Thyrotropin Releasing Hormone)
35 A Clinical Study to Evaluate the Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors Completed NCT01689727 Phase 2 Technetium Tc 99m EC20
36 A Multicenter, Open-label, Randomized, Phase II Study to Evaluate Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Pasireotide LAR in Japanese Patients With Active Acromegaly or Pituitary Gigantism Completed NCT01673646 Phase 2 Pasireotide LAR
37 An Open-Label, Single Arm, Phase II Study to Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma Completed NCT01283542 Phase 2 Pasireotide LAR
38 Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy Completed NCT00939523 Phase 2 Lapatinib
39 Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas Recruiting NCT03930771 Phase 2 Capecitabine;Temozolomide
40 Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Aggressive Pituitary Tumors Recruiting NCT04042753 Phase 2 Ipilimumab;Nivolumab;Nivolumab
41 A One Year, Randomized, Double-Blind, Placebo-Controlled Study of TBR-760 in Adult Patients With Non-Functioning Pituitary Adenomas Not yet recruiting NCT04335357 Phase 2 TBR-760;Placebo
42 Interstitial Radioactive Iodine Implants for the Treatment of Pan-invasive Pituitary Macroadenomas Terminated NCT01444209 Phase 2
43 Rosiglitazone (Peroxisome Proliferating Activating Receptor-gamma {PPAR-y} Ligand) Treatment of Pituitary Tumors Terminated NCT00616642 Phase 2 rosiglitazone maleate
44 An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rare Tumors of Neuroendocrine Origin Terminated NCT00958841 Phase 2 pasireotide LAR
45 Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Metastatic or Incurable Neuroendocrine Tumors Withdrawn NCT00003514 Phase 2 antineoplaston A10;antineoplaston AS2-1
46 Exploratory Phase 2 Study of Farletuzumab in Resectable Non-functioning Pituitary Adenoma Withdrawn NCT01203618 Phase 2 Farletuzumab
47 An Open Label, Multicenter, Phase II Study Evaluating the Safety and Efficacy of Temozolomide Treatment in Patients With Invasive Pituitary Tumors Withdrawn NCT00601289 Phase 2 temozolomide
48 A Phase II Study to Evaluate the Effects of 177Lu-DOTATATE in Patients With Unresectable and Progressive Rare Metastatic Endocrine Carcinomas: Medullary Thyroid Cancer, Parathyroid Carcinoma, Pituitary Carcinoma, and Malignant Pheochromocytoma/Paraganglioma Withdrawn NCT04106843 Phase 2 Lutetium Lu 177 Dotatate
49 Detection of Functioning Pituitary Microadenoma With Inconclusive MRI Findings: PET/MRI Versus PET/CT Unknown status NCT03404414 Phase 1 18F-FDG
50 An Open-label, Randomized, Two-period, Two-sequence Crossover Trial to Assess the Bioequivalence of the Liquid Formulation Versus the Freeze-dried Formulation of 900 IU r-hFSH and 450 IU r-hLH in Pergoveris®, Administered Subcutaneously in Pituitary Suppressed Healthy Premenopausal Female Subjects Completed NCT02317809 Phase 1 Liquid pergoveris;Freeze-dried pergoveris

Search NIH Clinical Center for Pituitary Gland Disease

Genetic Tests for Pituitary Gland Disease

Anatomical Context for Pituitary Gland Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Pituitary Gland Disease:

19
Pituitary Gland

MalaCards organs/tissues related to Pituitary Gland Disease:

40
Pituitary, Brain, Thyroid, Hypothalamus, Spinal Cord, Ovary, Prostate

Publications for Pituitary Gland Disease

Articles related to Pituitary Gland Disease:

(show top 50) (show all 1208)
# Title Authors PMID Year
1
The direct and indirect impact of the COVID-19 pandemic on the care of patients with pituitary disease: a cross sectional study. 42
33236181 2021
2
Important Management Considerations In Patients With Pituitary Disorders During The Time Of The Covid-19 Pandemic. 42
33471683 2020
3
Pituitary stalk interruption syndrome is characterized by genetic heterogeneity. 42
33270637 2020
4
Impact of the primary aetiology upon the clinical outcome of adults with childhood-onset GH deficiency. 54 61
17984238 2007
5
Systemic metabolic effects of combined insulin-like growth factor-I and growth hormone therapy in patients who have sustained acute traumatic brain injury. 54 61
17405254 2006
6
Predictive value of circulating insulin-like growth factor I levels in ischemic stroke outcome. 54 61
16882751 2006
7
[A case of primary hypothyroidism with pituitary enlargement and abnormal secretion of growth hormone and prolactin]. 54 61
7750626 1995
8
Pituitary gonadotrophin secretory capacity during the luteal phase in superovulation using GnRH-agonists and HMG in a desensitization or flare-up protocol. 61 54
1479002 1992
9
Hypogonadotropic hypogonadism in idiopathic hemochromatosis: evidence for combined hypothalamic and pituitary involvement. 61 54
2128941 1990
10
Experience of a Pituitary Clinic for US Military Veterans With Traumatic Brain Injury. 61
33655093 2021
11
Long-Term Outcomes of Pituitary Gland Preservation in Pituitary Macroadenoma Apoplexy: Case Series and Review of the Literature. 61
33777632 2021
12
Postoperative and Long-Term Endocrinologic Complications of Craniopharyngioma. 61
33794526 2021
13
Pituitary disease and recovery: How are stem cells involved? 61
33503464 2021
14
Giant calcified pseudoplasm of the nerve axis of the temporal lobe: a case report and review of the literature. 61
33675530 2021
15
Neuroinflammation and Hypothalamo-Pituitary Dysfunction: Focus of Traumatic Brain Injury. 61
33799967 2021
16
Diabetes insipidus with impaired vision caused by germinoma and perioptic meningeal seeding: A case report. 61
33748249 2021
17
Hypothalamic-pituitary dysfunction in alternating hemiplegia of childhood. 61
33756210 2021
18
Histopathological findings in the landscape of IgG4-related pathology in patients with pituitary dysfunction: Review of six cases. 61
33615590 2021
19
Current concepts of the diagnosis of adult growth hormone deficiency. 61
32959175 2021
20
Genetics of Azoospermia. 61
33806855 2021
21
Homozygous variant in MADD, encoding a Rab guanine nucleotide exchange factor, results in pleiotropic effects and a multisystemic disorder. 61
33723354 2021
22
Endoscopic extended transsphenoidal surgery for newly diagnosed paediatric craniopharyngiomas. 61
33665678 2021
23
Insights into the Regulation on Proliferation and Differentiation of Stem Leydig Cells. 61
33598893 2021
24
Hypothalamic-Pituitary Dysfunction - Part 2: Hypothalamic-Pituitary Dysfunctions Other Than Growth Hormone Deficiency in Cancer Survivors. 61
33556939 2021
25
Neuropathology of Septo-optic Dysplasia: A Report of 4 Autopsy Cases. 61
32921263 2021
26
Review of the MRI brain findings of septo-optic dysplasia. 61
33019967 2021
27
Primary pituitary granulomatosis with polyangiitis and the role of pituitary biopsy, case report and literature review. 61
33538207 2021
28
High Prevalence of Weight Gain in Childhood Brain Tumor Survivors and Its Association With Hypothalamic-Pituitary Dysfunction. 61
33621126 2021
29
Hypogonadism and liver fibrosis in HIV-infected patients. 61
33515211 2021
30
A case of isolated hypothalamitis with a literature review and a comparison with autoimmune hypophysitis. 61
32963149 2021
31
Differential macroscopic and histologic features between pituitary adenomas presenting with and without presurgical anterior pituitary dysfunction. A study of 232 patients. 61
33419702 2021
32
Utility of intraoperative ultrasonography for resection of pituitary adenomas: a comparative retrospective study. 61
33403430 2021
33
Adrenal disease: An update. 61
33543156 2021
34
Endoscopic Endonasal Approach to Giant Pituitary Adenomas: Surgical Outcomes and Review of the Literature. 61
33524611 2021
35
Neonatal respiratory distress produced by a nasopharyngeal glioma with a persistent craniopharyngeal canal. 61
32945599 2020
36
Pituitary metastasis of a breast ductal adenocarcinoma. 61
33235712 2020
37
Status and clinical and radiological predictive factors of presurgical anterior pituitary function in pituitary adenomas. Study of 232 patients. 61
32785896 2020
38
The importance of specialized sleep investigations in children with a suprasellar tumor. 61
32691357 2020
39
Prenatal diagnosis of isolated agenesis of the septum pellucidum with ultrasound and magnetic resonance imaging 61
33361505 2020
40
Pituitary Dysfunction in Patients with Intracranial Germ Cell Tumors Treated with Radiotherapy. 61
33471738 2020
41
Kisspeptin-54 accurately identifies hypothalamic GnRH neuronal dysfunction in men with congenital hypogonadotropic hypogonadism. 61
33227799 2020
42
Amelioration of cognitive impairment following growth hormone replacement therapy: A case report and review of literature. 61
33344573 2020
43
Nasopharyngeal B-cell lymphoma with pan-hypopituitarism and oculomotor nerve palsy: a case report and review of the literature. 61
33143716 2020
44
Endocrine Outcomes In Central Diabetes Insipidus: the Predictive Value of Neuroimaging "Mismatch Pattern". 61
32797230 2020
45
Anti-pituitary antibodies as a marker of autoimmunity in pituitary glands. 61
33055452 2020
46
Excess Mortality Among Hospitalized Patients With Hypopituitarism-A Population-Based, Matched-Cohort Study. 61
32785679 2020
47
Primary Pituitary Lymphoma As Rare Cause Of A Pituitary Mass And Hypopituitarism In Adulthood. 61
33471665 2020
48
Primary and Ipilimumab-induced Hypophysitis: A Single-center Case Series. 61
32892666 2020
49
Hypothalamic-Pituitary Axis Dysfunction after Whole Brain Radiotherapy - A Cohort Study. 61
32988906 2020
50
Anticancer Medications and Sodium Dysmetabolism. 61
33117443 2020

Variations for Pituitary Gland Disease

Expression for Pituitary Gland Disease

Search GEO for disease gene expression data for Pituitary Gland Disease.

Pathways for Pituitary Gland Disease

Pathways related to Pituitary Gland Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.19 TRH SST PRL POMC GNRH1 GHRH
2
Show member pathways
12.6 POMC MEN1 INS CRH AIP
3
Show member pathways
11.88 POMC INS IGF1 GH1
4
Show member pathways
11.7 SST POU1F1 POMC IGF1 GHRH GH1
5 11.62 POMC GHRH CRH AVP
6 11.49 PRL POU1F1 POMC
7 10.43 PRL POMC INS
8 10.21 POMC CRH

GO Terms for Pituitary Gland Disease

Cellular components related to Pituitary Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.9 TRH SST PRL POMC INS IGF1
2 secretory granule GO:0030141 9.43 TRH POMC AVP
3 extracellular space GO:0005615 9.36 SST PRL POMC MIR93 INS IGF1
4 endosome lumen GO:0031904 9.13 PRL INS GH1

Biological processes related to Pituitary Gland Disease according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.11 TRH PRL POMC INS IGF1 GNRH1
2 negative regulation of cell proliferation GO:0008285 9.91 SST POU1F1 MIR93 MEN1 GNRH1
3 positive regulation of cell proliferation GO:0008284 9.88 PRL INS IGF1 GHRH CRH AVP
4 cellular protein metabolic process GO:0044267 9.83 PRL MEN1 INS IGF1
5 G protein-coupled receptor signaling pathway GO:0007186 9.76 TRH SST POMC INS GNRH1 GHRH
6 female pregnancy GO:0007565 9.72 PRL GNRH1 CRH
7 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.71 INS IGF1 GH1
8 response to ethanol GO:0045471 9.67 TRH GNRH1 CRH AVP
9 positive regulation of glycogen biosynthetic process GO:0045725 9.57 INS IGF1
10 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.56 PRL GH1
11 ERK1 and ERK2 cascade GO:0070371 9.5 IGF1 HESX1 AVP
12 adenohypophysis development GO:0021984 9.49 POU1F1 GHRH
13 negative regulation of feeding behavior GO:2000252 9.48 TRH INS
14 hormone-mediated apoptotic signaling pathway GO:0008628 9.43 SST CRH
15 pituitary gland development GO:0021983 9.43 PROP1 LHX3 HESX1
16 cell-cell signaling GO:0007267 9.17 TRH SST POMC INS GNRH1 GHRH
17 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.13 IGF1 GHRH GH1

Molecular functions related to Pituitary Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.36 TRH SST PRL POMC INS IGF1
2 neuropeptide hormone activity GO:0005184 9.33 GHRH CRH AVP
3 insulin-like growth factor receptor binding GO:0005159 9.26 INS IGF1
4 prolactin receptor binding GO:0005148 8.96 PRL GH1

Sources for Pituitary Gland Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....